Industry Executives to Address Whether Stem Cell Therapies Can Turn the Traditional Pharma Model on Its Head
HAIFA, Israel, Feb 13, 2013 (GLOBE NEWSWIRE via COMTEX) -- In a release issued earlier today by Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), the date of the company's discussion at the 8 Annual New York Stem Cell Summit '13 had a typographical error. The roundtable discussion will be on February 19, 2013, not April 19. The corrected release follows:
Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that Zami Aberman, Chairman and Chief Executive Officer of Pluristem, will participate in a roundtable discussion at the 8 Annual New York Stem Cell Summit '13 on February 19, 2013. Mr. Aberman will join senior executives from Osiris Therapeutics, Inc., Mesoblast Limited, Athersys Inc., Promethera Biosciences and Garnet Biotherapeutics to discuss the topic, "Disrupting the Pharma Model with Allogeneic Stem Cell Therapies," and address the important question of whether stem cell therapies could turn the traditional Pharma model of drug discovery on its head. |
